GI-TONE-NUMATA
Sake’s geographical indication, “GI Tone-Numata,” which consists of four sake breweries in the Tone-Numata area of Gunma Prefecture in Japan, requires that the breweries make the most of the local water and climate, and that the type of rice used as the raw material be one of the following: Yukihotaka, Gohyakumangoku, or Koshihikari. In addition, only yeast from the local area (Gunma KAZE yeast, Gunma G2 yeast, and brewer's house yeast) can be used, and vintage can be indicated under certain conditions, so only those that meet the extremely strict criteria are certified.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006144/en/
According to Mr. Shinya Tasaki, Chairman of the Japan Sommelier Association, "GI Tone-Numata is equivalent to PDO in Europe or AOC in French wine and is expected to attract worldwide attention in the future." On January 17, "GI Tone-Numata" sake as a set of 7 bottles will be released for sale in overseas markets.
The seven kinds of “GI Tone-Numata” sake commonly have a transparent, pale gold color, and an aroma that contains the note of freshly made rice cakes, fruit, almond jelly, green grass, and fresh greenery. The flavors are characterized by a refreshing acidity, a bitterness that brings richness, a mellow umami and sweetness derived from rice, and a clear impression.
These seven types of certified sake, from sparkling sake for the “kanpai,” to full-flavored sake for the main course, then sweet dessert sake at the end of the meal, can be paired with French cuisine course meals. They go well with ingredients that are difficult to pair with wine, such as fresh tomatoes and eggs.
-
4 breweries of GI Tone-Numata
Otone Sake Brewery http://www.sadaijin.co.jp/
NAGAI SAKE INC. http://www.nagai-sake.co.jp/en/
Tsuchida Sake Brewery Co., Ltd. https://tsuchidasake.jp/en/
Nagai-honke Inc. https://www.nagaihonke.co.jp/
- The lineup of GI Tone-Numata certified sake and (the examples of) recommended food parings
- MIZUBASHO Yukihotaka AWA SAKE (NAGAI SAKE INC.) and Caprese Salad and Fruit Tomatoes
- Shin Tsuchida GI Tone-Numata Koshihikari (Tsuchida Sake Brewery Co., Ltd.) and Cold Roasted Duck with orange sauce
- Sadaijin Koshihikari (Otone Sake Brewery) and Penne carbonara
- Shin Tsuchida GI Tone-Numata Yukihotaka (Tsuchida Sake Brewery Co., Ltd.) and Scallop Meuniere, Provencal
- MIZUBASHO Yukihotaka Junmai Daiginjo (NAGAI SAKE INC.) and Vichyssoise
- TONENISHIKI JUNMAI KOSHIHIKARI 90 (Nagai-honke Inc.) and Akagi Chicken Fricassee with steamed vegetables
- MIZUBASHO Yukihotaka Dessert Sake (NAGAI SAKE INC.) and Strawberry Shortcake
-
For more information about each certified sake, please click here:
http://greencreate.boo.jp/PR/detail.pdf -
Contact information for purchase:
NAGAI SAKE INC. (English available)
Email info@mizubashou.co.jp -
“Seek the Story of Sake” e-commerce site (shipping only to Singapore and Hong Kong)
https://www.seekstorysake.com/pages/tonenumata -
Video highlights of the “GI Tone-Numata Online Symposium” held in November 2021
https://www.youtube.com/watch?v=rUzK3BpN668 -
Video of Sommelier Shinya Tasaki's visit to Tone-Numata
https://www.youtube.com/watch?v=ZOqApzYzZcU
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111006144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom